| Prev Close: | 104.54 |
|---|---|
| Open: | 105.06 |
| Bid: | 102.10 x 200 |
| Ask: | 106.20 x 100 |
| 1y Target Est: | 111.36 |
| Beta: | 0.54 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | 104.40 - 106.92 |
|---|---|
| 52wk Range: | 67.61 - 114.95 |
| Volume: | 2,919,770 |
| Avg Vol (3m): | 4,891,290 |
| Market Cap: | 79.19B |
| P/E (ttm): | 17.87 |
| EPS (ttm): | 5.91 |
| Div & Yield: | 1.88 (1.80%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Biotech Bulls Can Ignore The Warning Signs At Their Perilat Seeking Alpha(Thu 8:14PM EDT)
- UPDATE 2-Gilead profit rises, but sales of older HIV drugs dipat Reuters(Thu 6:28PM EDT)
- Final Glance: Biotechnology companiesAP(Thu 6:05PM EDT)
- Top Fund Buys Focus On Defensive Stocks, Housingat Investor's Business Daily(Thu 5:45PM EDT)
- UPDATE 1-Gilead profit rises 63 pct, sales of older HIV drugs dipat Reuters(Thu 5:00PM EDT)
- Midday Glance: Biotechnology companiesAP(Thu 1:25PM EDT)
- EPO Pills: A Challenge For Amgen And Johnson & Johnsonat Seeking Alpha(Thu 12:36PM EDT)
- Does Celgene Still Have Upside Potential?at Wall St. Cheat Sheet(Thu 12:28PM EDT)
- 3 Healthcare Stock Stories For Midweek Wellnessat Wall St. Cheat Sheet(Thu 8:34AM EDT)
- On the Call: Merck R&D director Roger PerlmutterAP(Wed, May 1)
- Amgen Drugs May Boost Survival During a Nuclear Attackat Bloomberg(Wed, May 1)
- Drugs from Amgen, others assessed by FDA as radiation treatmentsat Reuters(Wed, May 1)
- Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of CaliforniaPR Newswire(Wed, May 1)
- DreamWorks Gets a Thumbs Up and 4 More Analyst Upgrades To Knowat Wall St. Cheat Sheet(Wed, May 1)
- Earnings Beat at HospiraZacks(Wed, May 1)
Press Releases
- Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of CaliforniaPR Newswire(Wed, May 1)
- Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96PR Newswire(Tue, Apr 23)
- Amgen Announces Webcast of 2013 First Quarter Financial ResultsPR Newswire(Thu, Apr 18)
Reports
- AMGN: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- ValuEngine Detailed Valuation Report for AMGNValuEngine, Inc.(May 2)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(May 2)